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Abstract
Introduction and aim. Radiofrequency ablation (RFA) is effective in the treatment of unresectable hepatic tumors and
promising results have also been described in tumors of kidney, lung, brain, prostate, and breast. The radiofrequency
destruction of solid pancreatic tumors sounds logical but also seems risky due to the friable pancreatic parenchyma, the fear
of pancreatitis and the prejudiced myth of ‘the pancreas is not your friend’. Patients and methods. We present our initial
experience and we describe our technique during intraoperative RFA in four patients with locally advanced and
unresectable pancreatic adenocarcinoma (head of pancreas, three; body-tail, one; diameter, 3/12 cm). In all the patients,
the RFA was followed by bypass palliative procedures (cholecystojejunostomy and Brown’s anastomosis and/or
gastrojejunostomy). A drainage tube was left close to the ablated area. Serum amylase and fluid amylase (drain)
were measured for 5/7 days postoperatively. Sandostatin was also administered prophylactically for 3/5 days. Results. The
postoperative period was uneventful in all the patients, without complications or evidence of pancreatitis. The post
RFA CT scan showed remarkable changes in the density and the characteristics of the tumors in all the patients.
All the patients are alive, at 12, 8, 5 and 3 months postoperatively, respectively. In one patient (with cancer of the body
of the pancreas) who was receiving morphine because of intolerable pain, significant pain relief has been observed.
Conclusions. From our initial results, RFA seems to be a feasible, potentially safe and promising option in patients with
locally advanced and unresectable pancreatic cancer. Nevertheless, larger series of cases are needed to secure our
encouraging results.
Key Words: Radiofrequency ablation, pancreatic cancer, unresectable or locally advanced
Introduction
Pancreatic cancer is one of the most aggressive human
malignancies. Despite the advances in diagnosis
and therapeutic means the outcome for these patients
remains poor. Because of the insidious course and
rapid growth, tumors are diagnosed at an advanced
stage and therefore only the minority of these patients,
about 20%, can benefit from pancreatectomy (resec-
tion) [1]. An additional 20% of patients have localized
disease but are not resectable. In patients with
unresectable or locally advanced pancreatic cancer
several palliative therapeutic modalities have been
applied for tumor regression, local control, slowing
of growth and relief of pain/symptoms, such as
chemoradiation, intraoperative electron beam irradia-
tion/IORT, interstitial or intraluminal brachytherapy
[2/7]. It is well known that hyperthermia has
catastrophic or anti-tumor effects.
Radiofrequency ablation (RFA) as the new, local
thermal ablative therapy, is effective in the treatment
of unresectable hepatic tumors and promising results
have also been described in tumors of kidney, lung,
brain, prostate, and breast [8]. The local destruction
of solid pancreatic tumors by radiofrequency sounds
logical but it can also be deemed as risky because of
the ‘soft’, friable pancreatic tissue/parenchyma, the
fear of pancreatitis and the prejudiced myth of ‘the
pancreas is not your friend’.
Patients and methods
We present below our initial experience and we
describe our technique during intraoperative RFA
in patients with locally advanced and unresectable
pancreatic cancer. Since May 2004, four patients (two
male, two female, aged 59/79, mean/70 years)
presented or were referred to our department with
obstructive jaundice (three patients) because of tumor
(diameter/3/7 cm) of head of pancreas and one
with gastric outlet obstruction due to huge tumor
(diameter/10/12 cm) of the body of the pancreas.
Ultrasound (US) and computed tomography (CT)
scans were performed on all four patients. An attempt
to stent the oldest patient via ERCP had failed.
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All the patients underwent thorough exploratory
laparatomy in which the tumor was confirmed as
adenocarcinoma. All four patients had positive results
with fine needle aspiration and frozen section, frozen
section of hepatoduodenal lymph node was positive in
three of the four patients. The tumors were consid-
ered locally advanced and therefore unresectable. In
light of these results we decided to proceed with
palliative procedures and RFA of the tumors. In-
formed consent was obtained from the patients
preoperatively.
A Kocher mobilization of the duodenum and the
head of pancreas was performed / as far as this was
feasible / and RFA was performed (usually three
ablations were carried out, according to the overlapping
technique from 2 to 8 min) under direct vision of the
duodenum to avoid burn damage. Simultaneously
infusion/perfusion with cold normal saline of the areas
around the tumors was done during the ablation. We
used the latest Cool-tipTM RFAblation system (Radio-
nics), with the cooled electrode (17-gauge, 15 cm
with 3 cm length for rapid tumor destruction) and
the Cool-tip Cluster electrodes for the huge tumor of
the body of the pancreas (Figure 1A, B).
In all patients the RFA was followed by bypass
palliative procedures (cholecystojejunostomy and
Brown’s anastomosis and/or gastrojejunostomy). A
drainage tube was always left in the ablated area.
Serum amylase and fluid amylase (drain) were mea-
sured for 5 days postoperatively. Sandostatin was also
administered prophylactically for 3/5 days.
Results
In all the patients the postoperative period was
uneventful without complications or evidence of
pancreatitis. In all the patients the post RFA CT
scan showed remarkable changes in the density and
the characteristics of the tumor (Figure 2A, B). In one
patient the tumor (diameter/3 cm) could not be
detected in the CT scan 6 months post RFA (Figure
3A, B, C). In the others the tumors remained the
same size or decreased (Figure 4A, B). The tumor
marker CA 19-9 was decreased in all patients. In one
patient, who had cancer of the body of the pancreas
and was receiving morphine because of intolerable
pain, a significant level of pain relief was observed.
The patients are alive 12, 8, 5, and 3 months
postoperatively.
Discussion
The local selective destruction of solid tumors,
especially liver tumors, by RFA is now well estab-
lished. The application of this method in solid
pancreatic tumors is still at a very early stage and is
still undergoing research for safer results. The sensi-
tive, friable pancreatic tissue, the prejudice about the
‘unfriendly pancreas’ may still have an adverse effect
Figure 1. (A) Kocher mobilization and RFA of tumor of the head of pancreas. (B) RFA with cluster electrodes of the huge tumor of the
body of the pancreas.
Figure 2. (A) Tumor of head of pancreas (arrow) before RFA. (B) Changes in density of tumor 2 weeks post RFA.
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on this method. This may be the main explanation
why the latest references are very poor concerning
RFA and pancreatic tumors. Matsui et al. in 2000 [9],
first reported 20 patients with unresectable pancreatic
adenocarcinoma treated with RFA. This article
should be the continuity of a previous one from the
same team in Osaka, Japan [10]. Two patients (10%)
died from critical complications and there was no
difference in average survival (3 months) between the
treated and control group. The authors consider that
the method is relatively safe and could be interesting
to treat unresectable tumors without metastasis or
patients with benign pancreatic tumors such as
insulinomas and glucagonomas. Previously Goldberg
et al., in a porcine model trial, concluded that
endoscopic ultrasound-guided RFA can be used safely
to create discrete zones of coagulation necrosis in the
porcine pancreas [11]. More recently, Elias et al. [12]
reported their experience in two patients with pan-
creatic metastatic tumors (from renal cancer), who
died from severe post RFA necrotizing pancreatitis,
and concluded that because of severe complications,
RFA in the pancreas is not recommended.
We have taken the decision to start using RFA in
pancreatic cancer / partly because of our expertise
with RF in liver, partly from our observation that the
use of diathermy or argon in pancreatic resection was
not followed by pancreatitis / and the remarkable
uneventful early and late postoperative period of the
first patient encouraged us to use the method in other
cases as well. We believe that because of the differ-
ences between parenchyma in the pancreas and the
liver, the RFA sessions should be of shorter duration
for the pancreas (2/8 min). With the Cool-tipTM
Figure 3. (A) Cancer of head of pancreas before RFA (arrow). (B) Destruction of tumor 2 weeks post-RFA (arrow). (C) The tumor cannot
be detected 6 months post-RFA (arrow).
Figure 4. (A) A huge tumor of the body-tail of the pancreas (arrow) before RFA. (B) Destruction and regression of the tumor (arrow) 5
months post-RFA.
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(Radionics) device the tumor destruction is direct and
controllable, avoiding undesirable damage of normal
pancreatic tissue. Although we did not attempt the
procedure percutaneously (78% in our liver series),
we strongly believe that laparatomy has the advantage
of protecting the adjacent viscerals, by cooling the
area, to perform the ablation under direct vision.
Furthermore, we believe that as regards RFA in
pancreatic tumors (especially of the head of pancreas),
it is prudent to follow the RFA with palliative bypass
procedures such as cholecystojejunostomy and gastro-
jejunostomy. In this case the internal cooling of the
common bile duct is meaningless. A surprising result
was the pain relief observed in a patient with huge
tumor of the body of pancreas, who was almost
addicted to morphine because of the intolerable pain.
From our initial experience we conclude that RFA
appears to be a feasible, potentially safe and promising
option in patients with locally advanced and unre-
sectable pancreatic cancer. The observation of local
control (possibly slow growth) in large tumors and the
disappearance of small tumors (diameter/3 cm) post
RFA may result in longer survival and better quality of
life (i.e. less pain, cachexia) of these patients. We now
apply RFA as the standard approach in this type of
patient; nevertheless, a greater number of cases is
needed to support our encouraging results.
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